SynthesisBMC cardiovascular disorders2025
Comparative efficacy and safety of anticoagulant therapies in coronary artery disease: a network meta-analysis of randomized controlled trials.
Synthesis in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe most efficacious anticoagulant intervention for people with coronary artery disease (CAD) is still not clearly defined, highlighting the need for a comprehensive assessment of the available alternatives. Previous studies have assessed individual treatments, but a lack of integrated comparisons limits clinical decision-making. This investigation seeks to check how safe and effective a range of anticoagulant therapies for individuals suffering from CAD are through a network meta-analysis.
methodsA comprehensive study and NMA were performed, including data from Embase, MEDLINE, PubMed, and WoS through May 20, 2024. 11 RCTs were incorporated, encompassing 118,870 individuals suffering from CAD. Outcome measures focused on stroke, myocardial infarction, all-cause mortality, cardiovascular mortality, and bleeding risks. Effect sizes for categorical variables were measured by odds ratios (OR) with 95% CrIs.
resultsThe administration of Rivaroxaban at a dosage of 2.5 mg BID, in conjunction with Aspirin at 100 mg OD, has been shown to markedly diminish the incidence of stroke (OR: 0.56, 95% CrI: 0.48 to 0.66), myocardial infarction (OR: 0.72, 95% CrI: 0.57 to 0.90), all-cause mortality (OR: 0.77, 95% CrI: 0.60 to 0.98), and cardiovascular mortality (OR: 0.77, 95% CrI: 0.66 to 0.90) however, there is an elevated risk of bleeding. The administration of Rivaroxaban in dose of 2.5 mg BID demonstrated elevated SUCRA rankings in terms of both efficacy and safety, indicating a well-rounded profile.
conclusionThe administration of Rivaroxaban in dose of 2.5 mg BID, in conjunction with Aspirin at 100 mg OD, demonstrates efficacy in mitigating thrombotic occurrences among individuals with CAD; however, it concomitantly elevates the risk of bleeding complications. Administering Rivaroxaban in dose of 2.5 mg two times per day stands as a plausible alternative, achieving a commendable equilibrium between efficacy and safety. This study helps fill an important evidence gap in guiding optimal anticoagulant strategies for CAD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.